Samsung Biologics – BiotechReality – Information Intelligence System for Biopharma

Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), has reported record-breaking financial results for the fourth quarter and full fiscal year 2025. Driven by the full-scale utilization of its massive manufacturing infrastructure and strategic global partnerships, the company surpassed KRW 4.5 trillion in annual revenue, marking a significant milestone in its journey as a pure-play CDMO. Financial Performance: A Year of Explosive Growth For the full fiscal year 2025, Samsung Biologics recorded a consolidated revenue of KRW 4,557.0 billion, a robust 30.3% increase compared to the previous year. Operating profit for the year surged by 56.6% to reach KRW 2,069.2 billion, reflecting the company’s high operational efficiency and the successful ramp-up of its largest facility, Plant 4. The fourth quarter of 2025 was particularly strong, with revenue hitting KRW 1,285.7 billion (+35.3% YoY) and operating profit climbing to KRW 528.3 billion, a 67.9% jump from Q4 2024. This performance was underpinned by the full utilization of Plants 1, 2, and 3, alongside Plant 4, which reached maximum capacity in the third quarter of 2025. Metric (Consolidated)FY 2025FY 2024YoY ChangeRevenueKRW 4,557.0BKRW 3,497.1B+30.3%Operating ProfitKRW 2,069.2BKRW 1,321.4B+56.6%EBITDAKRW 2,439.1BKRW 1,622.2B+50.4% Read More: Johnson & Johnson Reports Record Q4 and 2025 Results; Targets $100 Billion Milestone for 2026 Strategic Milestones and Global Partnerships The company’s growth was fueled by high-value long-term contracts. In the fourth quarter alone, Samsung Biologics secured a landmark KRW 1.1 trillion manufacturing agreement with a major European pharmaceutical company. This deal contributed to a cumulative contract value exceeding USD 21 billion since the company's inception. Quality and regulatory excellence remained a cornerstone of operations, with the company reaching a cumulative 420 regulatory approvals as of year-end. Following a successful equity spin-off in late 2025, Samsung Biologics has reaffirmed its strategic focus as a pure-play CDMO, allowing for greater agility in meeting the evolving needs of the global biopharmaceutical market. Read More: Abbott Signals Accelerating Growth for 2026 Following Strong Q4 and 2025 Performance 2026 Outlook: Global Footprint and Next-Gen Modalities Looking ahead, Samsung Biologics has projected a revenue growth of 15–20% for 2026, excluding potential contributions from its planned U.S. acquisition. Key growth drivers for the coming years include: U.S. Manufacturing Entry: In December 2025, the company announced the acquisition of a manufacturing facility in Rockville, Maryland. The site features two CGMP plants with a combined 60 kL of drug substance capacity. The deal is expected to close in Q1 2026, marking a critical step in providing regional supply resilience for Western clients. Plant 5 and Bio Campus III: Plant 5 is scheduled to begin contributing to revenue in 2026. Simultaneously, the company has secured land for Bio Campus III, which will focus on next-generation modalities, including cell and gene therapies and antibody-drug conjugates (ADCs). Expanded Services: Under its ExellenS™ framework, the company is preparing a fully automated pre-filled syringe (PFS) line, expected to be CGMP-ready by 2027. Commitment to Sustainability Samsung Biologics continues to lead in ESG initiatives, earning an 'A' rating in Water Security from the Carbon Disclosure Project (CDP). As a Champion of the Sustainable Markets Initiative, the company is actively integrating ESG considerations across its entire value chain to ensure long-term environmental stewardship. Information: Samsung Biologics Last Modified:

Tag: Samsung Biologics

Samsung Biologics Reports Q4 Results, Achieves Record KRW 4.5 Trillion Revenue in 2025, Sets Sights on U.S. Expansion

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment